XML 67 R53.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Reporting (Tables)
12 Months Ended
Mar. 03, 2018
Segment Reporting  
Schedule of reconciliation of the Company's business segments to the condensed consolidated financial statements

 

                                                                                                                                                                                    

 

 

Retail
Pharmacy

 

Pharmacy
Services

 

Intersegment
Eliminations(1)

 

Consolidated

 

March 3, 2018:

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$

15,832,625

 

$

5,896,669

 

$

(200,326

)

$

21,528,968

 

Gross Profit

 

 

4,372,373

 

 

407,732

 

 

 

 

4,780,105

 

Adjusted EBITDA(2)

 

 

388,360

 

 

171,534

 

 

 

 

559,894

 

March 4, 2017:

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$

16,766,620

 

$

6,393,884

 

$

(232,964

)

$

22,927,540

 

Gross Profit

 

 

4,671,975

 

 

392,732

 

 

 

 

5,064,707

 

Adjusted EBITDA(2)

 

 

551,816

 

 

188,235

 

 

 

 

740,051

 

February 27, 2016:

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$

16,820,388

 

$

4,103,513

 

$

(153,664

)

$

20,770,237

 

Gross Profit

 

 

4,761,153

 

 

230,826

 

 

 

 

4,991,979

 

Adjusted EBITDA(2)

 

 

747,910

 

 

101,357

 

 

 

 

849,267

 


 

 

 

(1)          

Intersegment eliminations include intersegment revenues and corresponding cost of revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Retail Pharmacy and Pharmacy Services segments record the revenue on a stand-alone basis.

(2)          

See "Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures" in MD&A for additional details.

 

Schedule of reconciliation of net income to Adjusted EBITDA

 

                                                                                                                                                                                    

 

 

March 3,
2018
(52 weeks)

 

March 4,
2017
(53 weeks)

 

February 27,
2016
(52 weeks)

 

Net (loss) income from continuing operations

 

$

(349,532

)

$

4,080

 

$

102,088

 

Interest expense

 

 

202,768

 

 

200,065

 

 

186,132

 

Income tax expense

 

 

305,987

 

 

44,438

 

 

49,512

 

Depreciation and amortization expense

 

 

386,057

 

 

407,366

 

 

361,134

 

LIFO (credit) charge

 

 

(28,827

)

 

(3,721

)

 

7,892

 

Lease termination and impairment charges

 

 

58,765

 

 

45,778

 

 

40,477

 

Goodwill impairment

 

 

261,727

 

 

 

 

 

Loss on debt retirements, net

 

 

 

 

 

 

33,205

 

Walgreens Boots Alliance merger termination fee

 

 

(325,000

)

 

 

 

 

 

 

Other

 

 

47,949

 

 

42,045

 

 

68,827

 

​  

​  

​  

​  

​  

​  

Adjusted EBITDA from continuing operations

 

$

559,894

 

$

740,051

 

$

849,267

 

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

 

Schedule of balance sheet information for the Company's reportable segments

 

                                                                                                                                                                                    

 

 

Retail
Pharmacy

 

Pharmacy
Services

 

Eliminations(2)

 

Consolidated

 

March 3, 2018:

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Assets

 

$

6,089,343

 

$

2,954,953

 

$

(54,969

)

$

8,989,327

 

Goodwill

 

 

43,492

 

 

1,377,628

 

 

 

 

1,421,120

 

Additions to property and equipment and intangible assets

 

 

199,437

 

 

15,327

 

 

 

 

214,764

 

March 4, 2017:

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Assets

 

$

8,664,216

 

$

3,087,143

 

$

(157,607

)

$

11,593,752

 

Goodwill

 

 

43,492

 

 

1,639,355

 

 

 

 

1,682,847

 

Additions to property and equipment and intangible assets

 

 

281,072

 

 

12,725

 

 

 

 

293,797

 


 

 

 

(2)          

As of March 3, 2018 and March 4, 2017, intersegment eliminations include netting of the Pharmacy Services segment long-term deferred tax liability of $38,713 and $140,865, respectively, against the Retail Pharmacy segment long-term deferred tax asset for consolidation purposes in accordance with ASC 740, and intersegment accounts receivable of $16,256 and $16,742, respectively, that represents amounts owed from the Pharmacy Services segment to the Retail Pharmacy segment that are created when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products.